Bonus Material-18_2025 CHEST Pulmonary Hypertension Board REVIEW_Levine

Pdf Summary

This comprehensive 2025 CHEST Pulmonary Board Review by Dr. Deborah Jo Levine focuses on Pulmonary Hypertension (PH), a hemodynamic condition defined by a mean pulmonary artery pressure (mPAP) ≥20 mm Hg at rest, measured via right heart catheterization (RHC). PH is not a single disease but a spectrum of pathologies categorized into five groups based on etiology: Group 1 (Pulmonary Arterial Hypertension, PAH), Group 2 (PH due to left heart disease), Group 3 (PH due to lung diseases/hypoxia), Group 4 (chronic thromboembolic PH, CTEPH), and Group 5 (PH with unclear/multifactorial mechanisms). Groups 2 and 3 account for 90–95% of PH cases.<br /><br />The clinical classification addresses varying causes including idiopathic, heritable, drug/toxin-induced PAH, connective tissue disease (notably scleroderma), HIV, portal hypertension, congenital heart disease, and others like PVOD/PCH. Heritable PAH frequently involves BMPR2 mutations. Diagnosis relies heavily on echocardiography for screening, but RHC is mandatory for definitive diagnosis and hemodynamic classification. V/Q scanning remains the gold standard for screening CTEPH, as it is potentially curable via pulmonary endarterectomy.<br /><br />Risk stratification tools (ESC/ERS 3-strata, REVEAL 2.0) integrate clinical, biochemical (NT-proBNP), echocardiographic, exercise, and hemodynamic data to estimate 1-year mortality and guide management. Vasoreactivity testing is reserved for idiopathic/heritable/drug-induced PAH to identify candidates for calcium channel blockers.<br /><br />Management entails supportive care plus targeted therapies across the endothelin, nitric oxide, prostacyclin, and novel activin/BMP pathways. FDA-approved drugs include endothelin receptor antagonists (ambrisentan, bosentan), PDE5 inhibitors (sildenafil), sGC stimulators (riociguat), prostacyclin analogs (epoprostenol, treprostinil), and new agents like sotatercept. Therapy requires close monitoring and risk reassessment. Early referral for transplantation is essential in high-risk patients including those with connective tissue disease, PVOD, and severe Group 3 PH.<br /><br />Key takeaways: PH diagnosis mandates RHC; V/Q scan screening for CTEPH is critical; calcium channel blockers only benefit vasoreactive PAH subtypes; risk stratification and frequent monitoring guide effective therapy; and early multidisciplinary management including transplant evaluation improves outcomes.

Meta Tag

Concept Pulmonary Hypertension

Concept Pulmonary Artery Catheterization

Concept Pre-capillary Pulmonary Hypertension

Concept Pulmonary Arterial Hypertension

Concept Chronic Thromboembolic Pulmonary Hypertension

Keywords

pulmonary hypertension

PH

right heart catheterization

mean pulmonary artery pressure

pulmonary arterial hypertension

PAH

chronic thromboembolic PH

V/Q scan

risk stratification

vasoreactivity testing

endothelin receptor antagonists

sotatercept

Pulmonary Hypertension

Pulmonary Artery Catheterization

Pre-capillary Pulmonary Hypertension

Pulmonary Arterial Hypertension

Chronic Thromboembolic Pulmonary Hypertension